Creative Medical Technology (NASDAQ:CELZ) Issues Earnings Results

Creative Medical Technology (NASDAQ:CELZ) announced its quarterly earnings results on Friday. The company reported ($0.48) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.48), Zacks reports.

Creative Medical Technology Stock Up 1.7%

CELZ stock traded up $0.05 during midday trading on Friday, hitting $3.02. The company’s stock had a trading volume of 170,960 shares, compared to its average volume of 145,810. The stock has a market cap of $7.79 million, a price-to-earnings ratio of -1.04 and a beta of 2.05. The stock’s 50-day moving average price is $3.51 and its 200 day moving average price is $2.88. Creative Medical Technology has a 1 year low of $1.69 and a 1 year high of $6.90.

Analyst Upgrades and Downgrades

CELZ has been the subject of several analyst reports. Wall Street Zen upgraded shares of Creative Medical Technology to a “sell” rating in a report on Saturday, August 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Creative Medical Technology in a report on Wednesday. Finally, Zacks Research upgraded Creative Medical Technology to a “hold” rating in a report on Tuesday, August 12th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Reduce”.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.